Nature Communications (Apr 2022)
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
- Omar Alhalabi,
- Jianfeng Chen,
- Yuxue Zhang,
- Yang Lu,
- Qi Wang,
- Sumankalai Ramachandran,
- Rebecca Slack Tidwell,
- Guangchun Han,
- Xinmiao Yan,
- Jieru Meng,
- Ruiping Wang,
- Anh G. Hoang,
- Wei-Lien Wang,
- Jian Song,
- Lidia Lopez,
- Alex Andreev-Drakhlin,
- Arlene Siefker-Radtke,
- Xinqiao Zhang,
- William F. Benedict,
- Amishi Y. Shah,
- Jennifer Wang,
- Pavlos Msaouel,
- Miao Zhang,
- Charles C. Guo,
- Bogdan Czerniak,
- Carmen Behrens,
- Luisa Soto,
- Vassiliki Papadimitrakopoulou,
- Jeff Lewis,
- Waree Rinsurongkawong,
- Vadeerat Rinsurongkawong,
- Jack Lee,
- Jack Roth,
- Stephen Swisher,
- Ignacio Wistuba,
- John Heymach,
- Jing Wang,
- Matthew T. Campbell,
- Eleni Efstathiou,
- Mark Titus,
- Christopher J. Logothetis,
- Thai H. Ho,
- Jianjun Zhang,
- Linghua Wang,
- Jianjun Gao
Affiliations
- Omar Alhalabi
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jianfeng Chen
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Yuxue Zhang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Yang Lu
- Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center
- Qi Wang
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- Sumankalai Ramachandran
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Rebecca Slack Tidwell
- Department of Biostatistics,, The University of Texas MD Anderson Cancer Center
- Guangchun Han
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Xinmiao Yan
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Jieru Meng
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ruiping Wang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Anh G. Hoang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Wei-Lien Wang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jian Song
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Lidia Lopez
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Alex Andreev-Drakhlin
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Arlene Siefker-Radtke
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Xinqiao Zhang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- William F. Benedict
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Amishi Y. Shah
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jennifer Wang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Pavlos Msaouel
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Miao Zhang
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Charles C. Guo
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Bogdan Czerniak
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Carmen Behrens
- Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Luisa Soto
- Department of Translational molecular pathology, The University of Texas MD Anderson Cancer Center
- Vassiliki Papadimitrakopoulou
- Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jeff Lewis
- Department of Biostatistics,, The University of Texas MD Anderson Cancer Center
- Waree Rinsurongkawong
- Department of Biostatistics,, The University of Texas MD Anderson Cancer Center
- Vadeerat Rinsurongkawong
- Department of Biostatistics,, The University of Texas MD Anderson Cancer Center
- Jack Lee
- Department of Biostatistics,, The University of Texas MD Anderson Cancer Center
- Jack Roth
- Department of Thoracic and Cardiovascular surgery, The University of Texas MD Anderson Cancer Center
- Stephen Swisher
- Department of Thoracic and Cardiovascular surgery, The University of Texas MD Anderson Cancer Center
- Ignacio Wistuba
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- John Heymach
- Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jing Wang
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- Matthew T. Campbell
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Eleni Efstathiou
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Mark Titus
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Christopher J. Logothetis
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Thai H. Ho
- Division of Medical Oncology, Mayo Clinic
- Jianjun Zhang
- Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Linghua Wang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Jianjun Gao
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-022-29397-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
The deficiency of MTAP, an enzyme of the adenine salvage pathway, occurs in some cancers. Here the authors perform a small cohort phase II clinical trial with metastatic MTAP-deficient urothelial cancer (UC) and show an increased overall response when comparing to MTAP-proficient UC patients.
